We specialize in the discovery and development of immunotherapies addressing cancer, autoimmune, cardiovascular, and metabolic diseases. Our portfolio spans from preclinical to Phase III programs, all discovered internally. We actively pursue partnerships for out-licensing and strategic collaboration opportunities.